Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein

At present, treatment of HIV infection uses small inhibitory molecules that target HIV protease; however, the emergence of resistant HIV strains is increasingly problematic. To circumvent this, we report here a new 'Trojan horse' strategy to kill HIV-infected cells by exploiting HIV protease. We engineered a transducing, modified, apoptosis-promoting caspase-3 protein, TAT–Casp3, that substitutes HIV proteolytic cleavage sites for endogenous ones and efficiently transduces about 100% of cells, but remains inactive in uninfected cells. In HIV-infected cells, TAT–Casp3 becomes processed into an active form by HIV protease, resulting in apoptosis of the infected cell. This strategy could also be applied to other pathogens encoding specific proteases, such as hepatitis C virus, cytomegalovirus and malaria.

[1]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[2]  G M Cohen,et al.  Caspases: the executioners of apoptosis. , 1997, The Biochemical journal.

[3]  S. Gulnik,et al.  Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. , 1995, Biochemistry.

[4]  Xiaodong Wang,et al.  Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.

[5]  S. Lowe,et al.  Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. , 1998, Genes & development.

[6]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[7]  P. Henkart.  ICE family proteases: mediators of all apoptotic cell death? , 1996, Immunity.

[8]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[9]  S. Nagata,et al.  A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD , 1998, Nature.

[10]  W. Farmerie,et al.  Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. , 1996, Virology.

[11]  M. Schmidt,et al.  Regulation of intracellular human immunodeficiency virus type-1 protease activity. , 1998, Virology.

[12]  H. Gendelman,et al.  Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Dowdy,et al.  TCR antigen-induced cell death occurs from a late G1 phase cell cycle check point. , 1998, Immunity.

[14]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[15]  Mark L. Pearson,et al.  Complete nucleotide sequence of the AIDS virus, HTLV-III , 1985, Nature.

[16]  L. Everitt,et al.  Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H Nagahara,et al.  Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Xiang,et al.  BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  K. Elkon.  Caspases , 1999, The Journal of Experimental Medicine.

[20]  D. Sullivan,et al.  Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. , 1997, Annual review of microbiology.

[21]  J. Sodroski,et al.  Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Kappes,et al.  Functional RT and IN incorporated into HIV‐1 particles independently of the Gag/Pol precursor protein , 1997, The EMBO journal.

[23]  Natalie A. Lissy,et al.  Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration , 1998, Nature Medicine.

[24]  E D Blair,et al.  Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors , 1995, Antimicrobial agents and chemotherapy.

[25]  P. Coates.  Molecular Methods for the Identification of Apoptosis in Tissues , 1994 .

[26]  L J Davis,et al.  Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[27]  G. Salvesen,et al.  Caspases: Intracellular Signaling by Proteolysis , 1997, Cell.

[28]  W. Gibson,et al.  A herpesvirus maturational proteinase, assemblin: identification of its gene, putative active site domain, and cleavage site. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[29]  E. Lillehoj,et al.  Purification and structural characterization of the putative gag-pol protease of human immunodeficiency virus , 1988, Journal of virology.

[30]  P. Li,et al.  The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.